King Jonathan M, McManus Hamish, Gray Richard T, Nigro Steven J, Sisnowski Jana, Dobbins Timothy, Bavinton Benjamin R, Grulich Andrew E, Petoumenos Kathy, Costello Jane, McGregor Skye
The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Health Protection NSW, NSW Health, Sydney, New South Wales, Australia.
J Int AIDS Soc. 2024 Dec;27(12):e26399. doi: 10.1002/jia2.26399.
Due to a lack of robust population denominators, Australia is unable to accurately monitor changes in the HIV epidemic for some populations. The ratio of HIV transmission relative to the number of people with HIV (an incidence prevalence ratio, or IPR) can measure such changes. The IPR is measured against an IPR benchmark derived from post-HIV acquisition life expectancy, to indicate whether an HIV epidemic is shrinking or growing. Using IPRs and Australia-specific IPR benchmarks, this study aims to describe the Australian HIV epidemic among three groups: men with HIV attributed to male-to-male sex, women with HIV and people with HIV attributed to injection drug use.
Using mathematical modelling derived from HIV notifications, cohort and administrative data, IPRs were generated for each of the three groups. These IPRs were compared with IPR benchmarks derived from post-HIV acquisition mortality estimates using abridged life tables for men, women and people who inject drugs. The IPR benchmark for men was applied to people with HIV attributed to male-to-male sex. Trends in the IPR over time were described for each reported population from 2015 to 2022.
Overall, the IPR fell by 80%, from 0.040 (range: 0.034-0.045) in 2015 to 0.008 (range: 0.003-0.013) in 2022 and fell below the benchmark (0.022) in 2020. Among people with HIV attributed to male-to-male sex, the IPR fell by 85%, from 0.041 (range: 0.034-0.047) in 2015 to 0.006 (range: 0.003-0.024) in 2022 and fell below the benchmark (0.022) in 2020. Among women with HIV, the IPR fell by 56%, from 0.032 (range: 0.026-0.039) in 2015 to 0.014 (range: 0.003-0.029) in 2022 and fell below the benchmark (0.022) in 2019. Among people with HIV attributed to injection drug use, the IPR fell by 61%, from 0.036 (range: 0.022-0.047) in 2015 to 0.014 (range: 0.002-0.057) in 2022 and fell below the benchmark (0.028) in 2019.
Australian IPRs in all populations examined have dropped below the level required to sustain the HIV epidemic at current levels. By applying this method in other contexts, the changing scale of HIV epidemics may be better described for populations lacking robust population denominators.
由于缺乏可靠的人口基数,澳大利亚无法准确监测某些人群中艾滋病毒流行情况的变化。艾滋病毒传播率与艾滋病毒感染者数量之比(发病率患病率比,即IPR)可以衡量此类变化。IPR是相对于根据感染艾滋病毒后的预期寿命得出的IPR基准进行测量的,以表明艾滋病毒流行情况是在缩小还是在扩大。本研究旨在利用IPR和澳大利亚特定的IPR基准,描述三组人群中的澳大利亚艾滋病毒流行情况:因男男性行为感染艾滋病毒的男性、感染艾滋病毒的女性以及因注射吸毒感染艾滋病毒的人群。
利用从艾滋病毒通报、队列和行政数据得出的数学模型,为三组人群分别生成IPR。将这些IPR与根据男性、女性和注射吸毒者简略寿命表得出的感染艾滋病毒后的死亡率估计得出的IPR基准进行比较。男性的IPR基准应用于因男男性行为感染艾滋病毒的人群。描述了2015年至2022年各报告人群中IPR随时间的变化趋势。
总体而言,IPR下降了80%,从2015年的0.040(范围:0.034 - 0.045)降至2022年的0.008(范围:0.003 - 0.013),并在2020年降至基准值(0.022)以下。在因男男性行为感染艾滋病毒的人群中,IPR下降了85%,从2015年的0.041(范围:0.034 - 0.047)降至2022年的0.006(范围:0.003 - 0.024),并在2020年降至基准值(0.022)以下。在感染艾滋病毒的女性中,IPR下降了56%,从2015年的0.032(范围:0.026 - 0.039)降至2022年的0.014(范围:0.003 - 0.029),并在2019年降至基准值(0.022)以下。在因注射吸毒感染艾滋病毒的人群中,IPR下降了61%,从2015年的0.036(范围:0.022 - 0.047)降至2022年的0.014(范围:0.002 - 0.057),并在2019年降至基准值(0.028)以下。
在所有接受检查的人群中,澳大利亚的IPR已降至维持当前艾滋病毒流行水平所需的水平以下。通过在其他背景下应用此方法,对于缺乏可靠人口基数的人群,可能能够更好地描述艾滋病毒流行规模的变化。